Premier Bionics

Premier Bionics was an Australian medical technology and biotechnology company that specialized in the development of respiratory monitoring devices and therapeutic treatments for lung diseases. Listed on the Australian Securities Exchange (ASX: PBI), the company gained prominence for its acoustic sensing technology, which powered products like the Wheezometer for asthma monitoring and SleepSentry for sleep apnea. In 2008, the company expanded into drug development by acquiring assets from Pulmagen Therapeutics, including small molecule candidates for asthma and COPD. The company underwent significant rebranding, becoming iSonea Limited in 2011 and eventually Respiri Limited, shifting its focus toward digital health and mobile asthma management solutions.